Blood Cancer Journal

Our Current Treatment Algorithms section provides an expert outline for treatment of hematologic malignancies. See Myeloma algorithm by @VincentRK @myelomaMD @MayoCancerCare @MayoClinic #BCJ Experts interested in being an author should contact editors. nature.com/articles/s4140…

Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study | Blood Cancer Journal share.google/2fz5a7L5bvKo1v…

📄1/ Our multicenter real-world study of elranatamab in relapsed/refractory multiple myeloma is out today in @BloodCancerJnl. The main finding: outcomes in routine practice were meaningfully less favorable than those reported in MagnetisMM-3 cohort A. nature.com/articles/s4140…

@Myeloma_Society Link to paper @BloodCancerJnl referenced in the talk. nature.com/articles/s4140…

Sustained (3-5 years) of no evidence of cancer following a finite duration of therapy is often used as a surrogate for cure in patients with many cancers. On the other hand to consider a cancer a curable cancer we need to demonstrate a sustained (5 years or more) plateau in the the disease specific survival/ disease free survival following achievement of a disease free state and complete cessation of therapy.

What is cure in cancer? My talk at the recent IMS cure meeting using myeloma as an example.

Thanks Dr. Sonja Zweegman for taking this candid photo at a recent ⁦@Myeloma_Society⁩ meeting. My friends who have contributed a lot to the myeloma field. From left: Jesus San Miguel, Ken Anderson, Philippe Moreau, myself, and Nikhil Munshi. ⁦@NikhilMunshiMD⁩

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma @BloodCancerJnl nature.com/articles/s4140…

#mmsm @BloodCancerJnl Late neurotoxicity after Cilta-cel CAR-T in myeloma @YiLinMDPhD ✅Incidence: 6.4% nerve palsies (IEC-NP), 3.8% parkinsonism (IEC-PKS) ✅Key predictor: Peak lymphocyte count ≥3×10⁹/L 31% risk if high vs 2% if low 98% NPV for low counts ✅ Risk factors: -Age >75 years - significantly higher risk for parkinsonism (56% of IEC-PKS patients vs 5% controls) -High tumor burden at infusion - bone marrow plasma cells ≥20% or involved free light chain ≥20mg/dL increases IEC-PKS risk -ICANS development - associated with higher neurotoxicity risk 🛑In pts >75 years old with expected early access to BsAb, CAR-T will be risky with such high risk ➡️ rdcu.be/eXde1

#mmsm @BloodCancerJnl Late neurotoxicity after Cilta-cel CAR-T in myeloma @YiLinMDPhD ✅Timing: Neurotoxicity typically occurs 1-6 months post-infusion (median ~3 weeks) ✅ Outcomes: -IEC-NP: 93% complete resolution (median 57 days) -IEC-PKS: Early cyclophosphamide showed rapid improvement in 4/4 patients (1-2 days) -3 patients had severe multi-focal neurological involvement (phrenic nerve palsy, severe neuropathy) 🛑Mortality: 50-60% in severe IEC-PKS cases Imp with patient discussion and counseling

ALC ≥ 3K as a predictor of MNTs after cilta-cel in #MMsm: topic of many a discussion on rounds based on abstracts… now in print! Excellent @BloodCancerJnl work by #KennethLim @Rfonsi1 @Taxkourel @myelomaMD @YiLinMDPhD et al. Next q is whether dex works… more to come!

Late-onset cranial nerve palsies (6.4%) and parkinsonism (3.8%) after cilta-cel in RRMM (N=235). ALC peak 3x10e9 was a statistically significant predictor #mmsm #bmtsm @YiLinMDPhD @BloodCancerJnl nature.com/articles/s4140…

Honored to present at #ASH25 and to share the simultaneous publication of our study in @BloodCancerJnl on the same day! Anti-CD38-based quadruplet regimens significantly improve overall survival in transplant-ineligible multiple myeloma. #mmsm #myeloma doi.org/10.1038/s41408…

All my 2026 current myeloma algorithms in one thread. From smoldering to newly diagnosed to relapsed. Bookmark! #ASH25 #ASH25VR 1/ Smoldering Myeloma Main message: I recommend Daratumumab X 3 years for high risk smoldering myeloma.

Source

BCJ Editor in Chief @VincentRK with the highest impressions at #ASH25

OK here it is. Finally. My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD Give comments. I’m willing to adjust it based on your insights.

I need to follow a 100 more people posting on hematology and oncology. #ASH25 Give me some suggestions.

For #ASH25 attendees I’ve been on this platform for 16 years. Here are some tips on how to be productive, and gain influence and credibility on X. 1) Highlight new information, but also give your take on it as well. Thats what makes the content interesting. 2) Be active almost on a daily basis. This is important. 3) Writing is an art; writing on Twitter more so. Being simple and succinct is not easy. Keep at it. 4) Post some pics and some fun non-medical stuff now and then. You need to show your personality. 5) Only retweet content that you endorse. My retweets are always endorsements. (A like is like a mild retweet) 6) Use bookmarks for saving tweet to be read in the future. Don’t use the like button for this purpose. (I’m still struggling to comply with this! Old habits) 7) Critique, but don’t make your posts all negative. Be balanced. Assume positive intent. Your colleagues are also trying to do the right thing. It’s not easy to do the perfect study. 8) Avoid personal attacks at all costs 9) Don’t reply or engage with anyone who goes after you or attacks you. Engaging is amplifying. It’s not worth it. 10) Mute accounts that cause you distress. Liberally. You want to have a peaceful life. Block accounts if it’s really bothering you. 11) Engage with friends and colleagues with replies. Reply to those who reply to your tweet if possible. 12) Toggle your timeline to “Following” not “For You” to make sure you see content from people you follow and not random stuff. There’s a lot of it on here. 13) While it’s ok to give your general take on a particular medical condition, avoid providing direct medical advice on here. I can elaborate more on how to approach this very frequent situation on here. 14) Be kind and respectful. It’s very tempting to be snarky at times. Resist the urge. It’s in writing and permanent, so not worth it. 15)Follow the right people. 16) Posting content with pics or videos creates more engagement than text alone. 17) Make it clear on your profile that these are solely your personal opinions, unless you are posting in official or institutional capacity. 18) Have fun When used well, Twitter is an incredible platform for medicine. To learn and disseminate content, keep up to date, connect with colleagues, make new friends with people in diverse fields, and more.

Unprecedented. #ASH25 Tec-Dara in relapsed myeloma. @mvmateos

This figure from a poster presentation by @PlasmaCellPete at #ASH25 shows how complex treatment decisions have gotten in myeloma. It explains well why I’m struggling to finalize my #ASH25 algorithm for relapsed myeloma.